Algernon Pharmaceuticals Announces Last Patient Treated in Phase II Study of IPF and Chronic Cough

Algernon Pharmaceuticals Inc. announced that the last patient has completed the treatment period in its Phase II proof of concept study of NP-120 for idiopathic pulmonary fibrosis (IPF) and chronic cough.